Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182-185.
about
Angiogenesis inhibitors for the treatment of ovarian cancerAngiogenesis-inhibitors for the treatment of ovarian cancerA current review of targeted therapeutics for ovarian cancer.Targeted therapy in lymphoma.Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects.Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.Practical considerations in ovarian cancer chemotherapy.Protein tyrosine phosphatases: new markers and targets in oncology?Migration-inducing gene 7 promotes tumorigenesis and angiogenesis and independently predicts poor prognosis of epithelial ovarian cancer.Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphomaNew diagnostic and molecular characteristics of malignant mesothelioma.Drug-induced QT-interval prolongation: considerations for clinicians.Antiangiogenic therapies in epithelial ovarian cancer.Strong cross-talk between angiogenesis and EBV: do we need different treatment approaches in lymphoma cases with EBV and/or high angiogenic capacity.Malignant mesothelioma: Canadian perspective and research directions.Overexpressed genes in malignant pleural mesothelioma: implications in clinical management.
P2860
Q24234292-7952C8D5-4AF1-42BE-BE5A-DEC1DCD9B437Q24240350-0DB514C5-4070-47AA-B09F-1974A0478C59Q33580998-A1D614CB-2A24-441F-A420-4A9155332C23Q34413686-1A53E944-DFA7-40FF-A37F-2BBA3F5B2EB4Q34473451-4A2E220C-8E97-42FB-9062-48B1989114DEQ34642678-0BBDD69A-B9E2-48E8-BC75-5F06135B937FQ35076260-92FA5617-C7D0-43D0-B63C-C5C74291452FQ36485213-B943D710-9CED-400E-8E11-14554699FB81Q37317324-EAE481F5-600B-4E8E-89F5-EF79E2B49BD9Q37321798-599BCA93-62D9-4BE4-A404-929A53A1AA73Q37360580-C802C893-63CC-4A5F-B40E-F89520D1C959Q37767425-B81CA738-D11D-4F65-B553-C006D1297B16Q37832931-4F2F6DDC-E2CE-40A5-88C4-00D683A8A92DQ37938966-692F31F7-9CCD-47AC-A7AC-0D0BD25CEA53Q47098675-9E7D12D1-EB14-4FAB-A148-349FC7E80AA9Q52672878-D02425D9-F0C3-46CF-9D8F-25E0A25DA5EA
P2860
Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182-185.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Phase II testing of sunitinib: ...... ND Program Trials IND.182-185.
@ast
Phase II testing of sunitinib: ...... ND Program Trials IND.182-185.
@en
type
label
Phase II testing of sunitinib: ...... ND Program Trials IND.182-185.
@ast
Phase II testing of sunitinib: ...... ND Program Trials IND.182-185.
@en
prefLabel
Phase II testing of sunitinib: ...... ND Program Trials IND.182-185.
@ast
Phase II testing of sunitinib: ...... ND Program Trials IND.182-185.
@en
P2093
P2860
P356
P1433
P1476
Phase II testing of sunitinib: ...... ND Program Trials IND.182-185.
@en
P2093
Buckstein R
Eisenhauer E
P2860
P304
P356
10.3747/CO.2007.132
P577
2007-08-01T00:00:00Z